Implementing targeted region capture sequencing for the clinical detection of Alagille syndrome: An efficient and cost-effective method

2Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

Alagille syndrome (AGS) is a highly variable, autosomal dominant disease that affects multiple structures including the liver, heart, eyes, bones and face. Targeted region capture sequencing focuses on a panel of known pathogenic genes and provides a rapid, cost-effective and accurate method for molecular diagnosis. In a Chinese family, this method was used on the proband and Sanger sequencing was applied to validate the candidate mutation. A de novo heterozygous mutation (c.3254-3255insT p.Leu1085PhefsX24) of the jagged 1 gene was identified as the potential disease-causing gene mutation. In conclusion, the present study suggested that target region capture sequencing is an efficient, reliable and accurate approach for the clinical diagnosis of AGS. Furthermore, these results expand on the understanding of the pathogenesis of AGS.

Cite

CITATION STYLE

APA

Huang, T., Yang, G., Dang, X., Ao, F., Li, J., He, Y., … He, Q. (2017). Implementing targeted region capture sequencing for the clinical detection of Alagille syndrome: An efficient and cost-effective method. Molecular Medicine Reports, 16(5), 6876–6881. https://doi.org/10.3892/mmr.2017.7429

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free